mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures

References

• Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International society for peritoneal dialysis Ad Hoc committee on ultrafiltration management in peritoneal dialysis. Perit Dial Int. 2000;20:S43–S55.
   PubMedGoogle Scholar
• Brown MC, Simpson K, Kerssens JJ, Mactier RA, Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: A national cohort study. Clin J Am Soc Nephrol. 2009;4:1222–1229.
   PubMed Web of Science ®Google Scholar
• Korte MR, Sampimon DE Lingsma HF, et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int. 2011;31:269–278.
   PubMed Web of Science ®Google Scholar
• van Westrhenen R, Aten J, Hajji N, et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif. 2007;25:466–472.
   PubMed Web of Science ®Google Scholar
• Bozkurt D, Sipahi S, Cetin P, et al. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Perit Dial Int. 2009;29:S206–S210.
   Google Scholar
• Pletinck A, Vanholder R, Veys N, Van Biesen W. Protecting the peritoneal membrane: Factors beyond peritoneal dialysis solutions. Nat Rev Nephrol. 2012;8:542–550.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim YL, Lindholm B. Experimental encapsulating peritoneal sclerosis models: Pathogenesis and treatment. Perit Dial Int. 2008;28:S21–S28.
   Google Scholar
• Nakamoto H. Encapsulating peritoneal sclerosis – A clinician's approach to diagnosis and medical treatment. Perit Dial Int. 2005;25:S30–S38.
   PubMed Web of Science ®Google Scholar
• Lo WK, Kawanishi H. Encapsulating peritoneal sclerosis—Medical and surgical treatment. Perit Dial Int. 2009;29:S211–S214.
   Google Scholar
• Garosi G, Oreopoulos DG. No need for “expiry date” in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis. Int Urol Nephrol. 2009;41:903–907.
   PubMed Web of Science ®Google Scholar
• Garosi G, Mancianti N, Corciulo R, La Milia V, Virga G. Encapsulating peritoneal sclerosis. J Nephrol. 2013;26:177–187.
   PubMed Web of Science ®Google Scholar
• Ceri M, Unverdi S, Dogan M, et al. Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model. Int Urol Nephrol. 2012;44:977–982.
   PubMed Web of Science ®Google Scholar
• Duman S, Bozkurt D, Sipahi S, et al. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv Perit Dial. 2008;24:104–110.
   PubMedGoogle Scholar
• Aguilera A, Aroeira LS, Ramirez-Huesca M, et al. Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Int J Artif Organs. 2005;28:164–169.
   PubMed Web of Science ®Google Scholar
• Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ. Differential effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant. 2002;17:2278–2280.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: Treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24:3209–3215.
   PubMed Web of Science ®Google Scholar
• Mohamed AO, Kamar N, Nogier MB, Esposito L, Duffas JP, Rostaing L. Tamoxifen therapy in kidney-transplant patients presenting with severe encapsulating peritoneal sclerosis after treatment for acute humoral rejection. Exp Clin Transplant. 2009;7:164–167.
   PubMed Web of Science ®Google Scholar
• Temple S, Zaltzman J, Perl J. Development of encapsulating peritoneal sclerosis in a renal transplant recipient on sirolimus immunotherapy. Perit Dial Int. 2010;30:475–477.
   PubMed Web of Science ®Google Scholar
• Adamidis KN, Zachariou CA, Kopaka ME, et al. Sclerosing peritonitis presenting 2 years after renal transplantation in a former CAPD patient. Ren Fail. 2011;33:246–248.
   PubMed Web of Science ®Google Scholar
• Huddam B, Azak A, Koçak G, Başaran M, Voyvoda N, Duranay M. Additive effectiveness of everolimus plus tamoxifen therapy in treatment of encapsulating peritoneal sclerosis. Ren Fail. 2012;34:387–389.
   PubMed Web of Science ®Google Scholar
• da Silva N, Rocha S, Rocha L, Faria S, Costa T, Mota C. Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient. Pediatr Nephrol. 2012;27:1583–1588.
   PubMed Web of Science ®Google Scholar
• Debska-Slizien A, Konopa J, Januszko-Giergielewicz B, et al. Posttransplant encapsulating peritoneal sclerosis: Presentation of cases and review of the literature. J Nephrol. 2013;26:906–911.
   PubMed Web of Science ®Google Scholar
• Sud R, Garry L, Spicer ST, et al. A role for everolimus in post‐transplant encapsulating peritoneal sclerosis: First case report. Nephrology. 2014;19:27–30.
   PubMed Web of Science ®Google Scholar
• Romagnoli J, Pedroso JA, Salerno MP, Favi E, Spagnoletti G, Citterio F. Posttransplant encapsulating peritoneal sclerosis, long-term success with everolimus and low-dose CNI: A case report. Transplant Proc. 2014;46:2368–2370.
   PubMed Web of Science ®Google Scholar
• Frascà GM, D’Arezzo M, Ricciatti AM, et al. m-TOR inhibitors may be useful in the treatment of encapsulating peritoneal sclerosis (EPS). J Nephrol. 2014;27:587–590.
   PubMed Web of Science ®Google Scholar
• Messina M, Ariaudo C, Mella A, Cantaluppi V, Segoloni GP, Biancone L. mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: A favourable single center experience. J Nephrol. 2015;28:245–249.
   PubMed Web of Science ®Google Scholar
• Pozdzik AA, Fernandez V, Demetter P, et al. Encapsulating peritoneal sclerosis in a kidney graft recipient unmaskedödöd by everolimus switch. Perit Dial Int. 2015;35:769–771.
   PubMed Web of Science ®Google Scholar